Key points are not available for this paper at this time.
Background : Nanotechnology has introduced several clinically validated drug-delivery platforms that have improved pharmacokinetic profiles and reduced selected toxicities in specific cancer indications. Materials and methods : This review was conducted by searching search engines such as Google Scholar, PubMed, and ScienceDirect using several keywords, such as “nanomedicine,” “lipid-based carriers,” “polymeric nanoparticles,” “dendrimers,” and “precision medicine.” The articles on precision medicine related to targeted therapy and gene therapy, artificial intelligence, and related large language models were excluded, and publications with unreliable, unverifiable, or inaccessible data, including non-peer-reviewed sources, were also excluded. Results : Recent advancements have also enabled the integration of diagnostic and therapeutic functions within a single nanocarrier, paving the way for theranostic applications and real-time treatment monitoring. Despite these significant achievements, challenges such as large-scale manufacturing, stability, immunogenicity, and long-term safety remain substantial barriers to clinical translation. Conclusion : Continuous efforts to develop biocompatible, cost-effective, and personalized nanomedicine platforms are essential to transform nanotechnology-based drug delivery from an experimental concept into a reliable clinical reality that has demonstrated improved pharmacokinetics, tolerability, or clinical outcomes in selected indications, such as liposomal formulations including CPX-351 and pegylated liposomal doxorubicin.
Jabbar et al. (Tue,) studied this question.